Selective cytotoxicity of solamargine via oxidative stress and caspase-independent mechanisms in human glioblastoma cells

Investigational New Drugs · Published 2026-02-01 · DOI 10.1007/s10637-026-01599-y

Free full text

Authors being retrieved — see the publisher record. https://doi.org/10.1007/s10637-026-01599-y

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Related articles

• Association of different approvals with Chinese Society of Clinical Oncology recommendation levels for solid tumor drugs: a cross-sectional analysis · Investigational New Drugs · 2025 · Same journal
• Clinical potential of antibody–drug conjugates in early-phase clinical trials for late-line treatment of advanced solid tumors · Investigational New Drugs · 2025 · Same journal
• Anti-CD47 tri-specific killer engager enhances NK cell cytotoxicity against lung cancer · Investigational New Drugs · 2025 · Same journal
• A phase I study of TRK-950, an Anti-CAPRIN-1 antibody, as monotherapy and in combination with nivolumab in Japanese patients with advanced solid tumors · Investigational New Drugs · 2026 · Same journal
• Beyond the obvious: targeting the SLC transportome and non-canonical drug transport mechanisms in cancer therapy · Investigational New Drugs · 2025 · Same journal
• Crocetin suppresses colorectal cancer progression by targeting TGM2 and inhibiting the JAK2/STAT3 pathway · Investigational New Drugs · 2026 · Same journal
• ABCB1 and ABCC10 polymorphisms predict sensitivity to first- and third-generation EGFR-TKIs in EGFR-mutant NSCLC · Investigational New Drugs · 2025 · Same journal
• Class-level DILI saturation and hERG-driven risk stratification among 2024–2025 FDA-approved kinase inhibitors: an in silico multi-platform safety analysis · Investigational New Drugs · 2026 · Same journal
• Patient-derived tumor organoids for new drug development: promises and challenges · Investigational New Drugs · 2026 · Same journal
• Phase 1/2, open-label study of oral bacterial supplementation (EDP1503) plus pembrolizumab in participants with advanced or metastatic microsatellite-stable colorectal cancer, triple-negative breast cancer, and checkpoint inhibitor–relapsed tumors · Investigational New Drugs · 2025 · Same journal